On 11 April 2019, the FDA further expanded its approval of pembrolizumab in NSCLC as a first-line monotherapy for patients with stage 3 NSCLC who cannot undergo surgical resection as well as chemoradiation or metastatic NSCLC with PDL-1 expression ≥1% and no EGFR or ALK mutation. The gene discussed is ALK; the disease is non-small cell lung carcinoma.